Skip to main content
. 2018 Nov 2;9:1260. doi: 10.3389/fphar.2018.01260

FIGURE 3.

FIGURE 3

Examples of passively targeted drug-loaded PLGA NPs. (A) Illustration of a drug-loaded stealth PLGA NP. (B) Antitumor effect of passive targeted PTX-loaded NPs and PTX (Taxol®) on mice with orthotopic hepatocellular carcinomas. Untreated control animals received PBS injection. The control treatments groups received PTX-loaded NPs or PTX only. Highest response was shown for the nanomedicine formulation (∗p < 0.05). Reprinted from Danhier et al. (2009) with permission from Elsevier. (C) The survival rate of colorectal adenocarcinoma HT 29 tumor-bearing mice injected intravenously with cisplatin-loaded PEGylated-PLGA NPs is higher than for the free drug, naive control and vehicle control. Figure reprinted from Mattheolabakis et al. (2009) with permission from Elsevier. (D) Phagocytic uptake efficiency of PTX-loaded PLGA NPs in dependence of the surface modification with different amount of PEG with varying Mw. Results showed that NPs with 10% of 2 kDa PEG Mw, along with 12% CS were most efficient in terms of evading phagocytic uptake and consequently are expected to have the most prolonged blood circulation time (∗p < 0.05). Reprinted from Parveen and Sahoo (2011) with permission from Elsevier.